Table 3.
Characteristic | N | Median survival | 2-year survival | P1 |
---|---|---|---|---|
Treatment regimen | ||||
Group 1 (Adjuvant TMZ only) | 21 | 15.6 months | 36% | 0.0495 |
Group 2 (Concurrenent & adjuvant TMZ) | 22 | 25.5 months | 51% | |
Age | ||||
Age ≤ 50 years | 12 | -- Not met -- | 80% | 0.0299 |
Age > 50 years | 31 | 16.9 months | 32% | |
Resection status | ||||
Biopsy | 11 | 10.3 months | 0% | |
STR | 20 | 28.7 months | 53% | 0.00022 |
GTR | 12 | 28.3 months | 60% | 0.43953 |
KPS | ||||
<70 | 13 | 15.6 months | 35% | 0.1212 |
≥70 | 30 | 23 months | 48% | |
RPA class | ||||
3 | 6 | -- Not met -- | 80% | |
4 | 17 | 28.7 months | 63% | 0.0139 |
5 | 13 | 17.6 months | 23% | |
6 | 7 | 10.3 months | 14% |
All p values derived from log-rank test.
Survival differences between biopsy, STR and GTR.
Survival difference between STR and GTR.